Inventor · disambiguated record
Florence Guimberteau
Also filed as: GUIMBERTEAU FLORENCE
24 granted patents·29 pending applications·591 citations·filing 1998–2024
96Inventor score
Files withCEVA SANTE ANIMALE14FLAMEL TECH SA11FLAMEL TECHNOLOGIES S A7GUIMBERTEAU FLORENCE7FLAMEL IRELAND LTD5
Top patents by PatentIndex Score
53 records- 0198USRE47084EOral medicinal product with modified release of at least one active principle in multimicrocapsular formFLAMEL IRELAND LTD·Filed 2016·Granted Oct 16, 2018·36 cites·74 claims
- 0298US9814684B2Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)FLAMEL IRELAND LTD·Filed 2015·Granted Nov 14, 2017·36 cites·31 claims
- 0398US7906145B2Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)FLAMEL TECH SA·Filed 2003·Granted Mar 15, 2011·101 cites·25 claims
- 0497US10004693B2Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)CASTAN CATHERINE·Filed 2011·Granted Jun 26, 2018·36 cites·24 claims
- 0597US8652529B2Anti-misuse microparticulate oral pharmaceutical formGUIMBERTEAU FLORENCE·Filed 2006·Granted Feb 18, 2014·78 cites·44 claims
- 0697US8445023B2Anti-misuse microparticulate oral pharmaceutical formGUIMBERTEAU FLORENCE·Filed 2009·Granted May 21, 2013·94 cites·31 claims
- 0796US9023400B2Prolonged-release multimicroparticulate oral pharmaceutical formGUIMBERTEAU FLORENCE·Filed 2007·Granted May 5, 2015·54 cites·55 claims
- 0894US8821935B2Microcapsules with modified release of active principles with low solubility for oral deliveryGUIMBERTEAU FLORENCE·Filed 2006·Granted Sep 2, 2014·42 cites·15 claims
- 0992US8895063B2Oral dosage form comprising an antimisuse systemGUIMBERTEAU FLORENCE·Filed 2007·Granted Nov 25, 2014·12 cites·42 claims
- 1092US8652523B2Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubilityGUIMBERTEAU FLORENCE·Filed 2003·Granted Feb 18, 2014·42 cites·14 claims
- 1191US11903947B2Triazine formulations with a second active ingredient and surfactant(s)CEVA SANTE ANIMALE·Filed 2022·Granted Feb 20, 2024·1 cites·24 claims
- 1291US8734850B2Oral medicinal product with modified release of at least one active principle in multimicrocapsular formCASTAN CATHERINE·Filed 2004·Granted May 27, 2014·39 cites·28 claims
- 1382US11331321B2Triazine formulations with a second active ingredient and surfactant(s)CEVA SANTE ANIMALE·Filed 2013·Granted May 17, 2022·3 cites·26 claims
- 1480US7910133B2Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillinFLAMEL TECH SA·Filed 2003·Granted Mar 22, 2011·8 cites·24 claims
- 1577US11903946B2Triazine formulations with a second active ingredient and surfactant(s)CEVA SANTE ANIMALE·Filed 2021·Granted Feb 20, 2024·0 cites·27 claims
- 1676US11911391B2Triazine formulations with a second active ingredient and surfactant(s)CEVA SANTE ANIMALE·Filed 2021·Granted Feb 27, 2024·0 cites·23 claims
- 1766US2017281558A1Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s).FLAMEL IRELAND LTD·Filed 2017·Application pending·0 cites
- 1866US2007264346A1Multimicroparticulate pharmaceutical forms for oral administrationFLAMEL TECH SA·Filed 2007·Application pending·0 cites
- 1965US2007173464A1Oral ribavirin pharmaceutical compositionsFLAMEL TECH SA·Filed 2007·Application pending·0 cites
- 2064US2014072644A1Anti-misuse microparticulate oral pharmaceutical formFLAMEL TECH SA·Filed 2013·Application pending·0 cites
- 2163US2009291137A1Solid oral form provided with a double release profileFLAMEL TECHNOLOGIES S A·Filed 2009·Application pending·0 cites
- 2262US12257226B2Veterinary compositions and the uses thereof for controlling iron deficiencies in non-human mammalsCEVA SANTE ANIMALE·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 2361US2007166378A1Oral ribavirin pharmaceutical compositionsFLAMEL TECHNOLOGIES INC·Filed 2006·Application pending·0 cites
- 2461US2010266701A1Anti-misuse microparticulate oral drug formFLAMEL TECHNOLOGIES S A·Filed 2009·Application pending·0 cites
- 2560US11090270B2Palatable oral veterinary compositionsCEVA SANTE ANIMALE·Filed 2020·Granted Aug 17, 2021·0 cites·7 claims
- 2660US11020350B2Palatable oral veterinary compositionsCEVA SANTE ANIMALE·Filed 2013·Granted Jun 1, 2021·0 cites·6 claims
- 2759US2006275376A1Microcapsules with modified release of active principles with low solubility for oral deliveryGUIMBERTEAU FLORENCE·Filed 2003·Application pending·0 cites
- 2859US2024180928A1Controlled-release progesterone compositions and uses thereofCEVA SANTE ANIMALE·Filed 2022·Application pending·0 cites
- 2958US2016338966A1Multimicroparticulate pharmaceutical forms foe oral administrationFLAMEL IRELAND LTD·Filed 2016·Application pending·0 cites
- 3057US2011104266A1Multimicroparticulate pharmaceutical forms for oral administrationFLAMEL TECH SA·Filed 2011·Application pending·0 cites
- 3157US2007264326A1Anti-misuse oral microparticle medicinal formulationFLAMEL TECH SA·Filed 2007·Application pending·0 cites
- 3255US12342792B2Nose ring for ruminantsCEVA SANTE ANIMALE·Filed 2022·Granted Jul 1, 2025·0 cites·17 claims
- 3355US11318156B2Solid injectable veterinary implants comprising monocyclic lactoneCEVA SANTE ANIMALE·Filed 2018·Granted May 3, 2022·0 cites·8 claims
- 3455US2009220611A1Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising SameDARGELAS FREDERIC·Filed 2006·Application pending·0 cites
- 3554US2009311315A1Multimicroparticulate Oral Pharmaceutical Form with Modified Release of Angiotensin II Receptor AntagonistsFLAMEL TECHNOLOGIES S A·Filed 2006·Application pending·0 cites
- 3654US2011129539A1Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for modified release of amoxicillinFLAMEL TECH SA·Filed 2011·Application pending·0 cites
- 3753US2008260844A1Solid, Oral, Microparticulate Dosage Form Which Has Been Designed To Prevent MisuseFLAMEL TECH SA·Filed 2005·Application pending·0 cites
- 3852US2004208936A1Novel compositionsFiled 2003·Application pending·0 cites
- 3952US2009041838A1Anti-Misuse Microparticulate Oral Drug FormFLAMEL TECHNOLOGIES S A·Filed 2006·Application pending·0 cites
- 4051US2008026056A1Antibiotic-Based Pharmaceutical Formulation in Microcapsular FormFLAMEL TECH SA·Filed 2005·Application pending·0 cites
- 4150US2007202049A1Oral dosage form comprising an antimisuse systemFLAMEL TECHNOLOGIES INC·Filed 2006·Application pending·0 cites
- 4250US2015313846A1Prolonged-release multimicroparticulate oral pharmaceutical formFLAMEL IRELAND LTD·Filed 2015·Application pending·0 cites
- 4347US11872208B2Composition for treating parasites infestationsCEVA SANTE ANIMALE·Filed 2018·Granted Jan 16, 2024·0 cites·13 claims
- 4446US2022257809A1Polymer packaging and use thereof for preserving a pharmaceutical compositionCEVA SANTE ANIMALE S A·Filed 2020·Application pending·0 cites
- 4544US2010009005A1Novel acetysalicylic acid formulationsFLAMEL TECHNOLOGIES S A·Filed 2006·Application pending·0 cites
- 4644US2011159088A1ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONSFLAMEL TECHNOLOGIES S A·Filed 2006·Application pending·0 cites
- 4744US2009123536A1Oral Pharmaceutical Form of LosartanFLAMEL TECHNOLOGIES S A·Filed 2006·Application pending·0 cites
- 4843US2008305160A1Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule FormFLAMEL TECH SA·Filed 2005·Application pending·0 cites
- 4940US6602917B1Method for preparing concentrated and emulsions calibrated in a highly viscous phase, in particular bitumen emulsionsCENTRE NAT RECH SCIENT·Filed 1998·Granted Aug 5, 2003·9 cites·22 claims
- 5040US2020281848A1Composition containing moxidectin for treating parasites infestationsCEVA SANTE ANIMALE·Filed 2018·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →